Bayer's Lung Cancer Drug Gets Breakthrough Therapy Status in China
By Helena Smolak
Bayer received breakthrough therapy designation for its experimental lung cancer drug from China's Center for Drug Evaluation, accelerating its development and potential access for patients.
The German pharmaceutical and biotechnology company said on Tuesday that it is currently evaluating its targeted therapy in Phase 1 and 2 trials for the treatment of inoperable or metastatic non-small cell lung cancer with activating HER2 mutations.
The drug received breakthrough therapy designation from the U.S. Food and Drug Administration in February.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
June 11, 2024 04:58 ET (08:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued